Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
In view of the Europe 2020 strategy for smart, sustainable and inclusive growth and th current economic and societal challenges it is of utmost importance to tackle key healt research targets. A major effort on SME participation will stimulate innovation, increase th participation of SMEs in clinical trials, increase the drive to develop of new therapies technologies and drugs to marketable products, and thus create a considerable Europea added value in the European health research area. Research-intensive SMEs must be attracte to participate in the Health Theme to ensure that new research and development (R&D findings are brought to the market and to. | DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare Medicaid Services 42 CFR Parts 410 414 415 421 423 425 486 and 495 CMS-1590-FC RIN 0938-AR11 Medicare Program Revisions to Payment Policies Under the Physician Fee Schedule DME Face-to-Face Encounters Elimination of the Requirement for Termination of Non-Random Prepayment Complex Medical Review and Other Revisions to Part B for CY 2013 AGENCY Centers for Medicare Medicaid Services CMS HHS. ACTION Final rule with comment period. SUMMARY This major final rule with comment period addresses changes to the physician fee schedule payments for Part B drugs and other Medicare Part B payment policies to ensure that our payment systems are updated to reflect changes in medical practice and the relative value of services. It also implements provisions of the Affordable Care Act by establishing a face-to-face encounter as a condition of payment for certain durable medical equipment DME items. In addition it implements statutory changes regarding the termination of non-random prepayment review. This final rule with comment period also includes a discussion in the Supplementary Information regarding various programs . See the Table of Contents for a listing of the specific issues addressed in this final rule with comment period. DATES Effective date The provisions of this final rule with comment period are effective on January 1 2013 with the exception of provisions in 410.38 which are effective on July 1 2013. The incorporation by reference of certain publications listed in the rule was approved by the Director of the Federal Register on May 16 2012. Comment date To be assured consideration comments must be received at one of the addresses provided below no later than 5 p.m. on OFR insert date 60 days after the date of filing for 2 public inspection at OFR. See the SUPPLEMENTARY INFORMATION section of this final rule with comment period for a list of the provisions open for comment. ADDRESSES In commenting please .
